Peacocks Medical Group (United Kingdom)

A detailed understanding of the risk factors for and impacts of body mass index (BMI) progression in people living with obesity is vitally needed. In this retrospective observational study, we examined the relationships between BMI progression, obesity-related complications (ORCs) and healthcare costs in individuals living with overweight or obesity in the UK. Data were from the Discover database of linked primary and secondary care records from 2.7million individuals in North West London, UK. Included individuals were ≥ 18years old, had a BMI of ≥ 25.0kg/m2 at index (date of first eligible BMI measurement during the study period: 1 January 2007 to 31 December 2019) and had no evidence of intentional weight loss. We examined BMI progression (increase) of ≥ 5% and ≥ 10% over 8years in demographic and ORC subgroups, and compared ORCs and costs between groups with and without BMI progression. In total, 290,051 individuals were included, of whom 31.4% experienced BMI progression of ≥ 5% during follow-up, with most progression occurring from year1 to year3. Proportions of individuals with ≥ 5% BMI progression were highest in the following subgroups: 18-29years (45.8%), 30-39years (39.2%), polycystic ovary syndrome (41.4%), asthma (34.5%), depression (33.9%) and women (33.9%). Total annual healthcare costs per person per year were £1000 for those with no BMI progression, £1143 for those with 5 to < 10% progression and £1251 for those with ≥ 10% progression. Groups with progression were more likely to develop ≥ 3 ORCs than those without. Younger adults, women and people with specific ORCs were most likely to experience BMI progression, which was associated with increased health and economic burden. Targeting high-risk subgroups with interventions to prevent weight gain could limit the clinical and economic impacts of obesity.

ObjectivesTo estimate the impact of COVID-19 infection on the requirement for social care services among adults aged ≥50 years in North-West London.DesignPopulation-based matched cohort study using linked routinely collected electronic social care, primary care and hospital records (the Discover dataset).SettingApproximately 4.7 million people with a general practitioner record in North-West London.Participants150 654 adults aged ≥50 years with a first diagnosis of COVID-19 between January 2020 and February 2023 and 547 704 propensity score matched comparators without a COVID-19 diagnosis during the same period.Main outcome measuresSocial care use and associated costs overall and by specific type (care home, domiciliary care, respite care, social care assessments) stratified by age group, index year, diagnosis setting, severe COVID-19 risk status, frailty and care home admission prior to index. Overall survival was also assessed.ResultsA total of 9174 (6.09%) individuals with COVID-19 required social care use (of any type) during follow-up, 2.54 times (95% CI 2.48 to 2.61; p<0.0001) higher than matched comparators (n=13 126, 2.40%). The difference was largest for care home admission; individuals with COVID-19 had 4.10 (95% CI 3.87 to 4.36; p<0.0001) times the risk of a care home admission and nearly twice the risk (risk ratio 1.94; 95% CI 1.86 to 2.02; p<0.0001) of domiciliary care during follow-up compared with matched comparators. Individuals with COVID-19 experienced higher mortality, with 9.30% (14 005/547 704) dying during follow-up compared with 3.76% (20 608/547 704) deaths among matched comparators.This increase in social care utilisation was observed for all age groups. Adults with COVID-19 had over four times higher social care costs than matched comparators (£1276 per person per year (pppy) vs £276 pppy; mean difference +£1000, 95% CI £947 to £1054, p<0.0001), with most of the costs due to care home admissions. Higher social care costs in individuals with COVID-19 compared with matched comparators were strongly age related, rising from a mean difference of £130 pppy (95% CI £99 to £161) in those aged 50–64 to £6108 pppy (95% CI £5613 to £6603) higher costs in those aged ≥85.ConclusionsCOVID-19 infection is associated with meaningfully higher social care requirements in the ≥50 years population. Reducing the need for social care use and the associated costs of care should be one of the goals of interventions to reduce the risk and severity of COVID-19 infection.

Cell-based therapy (CBT) has garnered significant interest as a potential treatment for incurable diseases. In CBT, the cells are the final products and require stringent processes in terms of safely delivering them to patients. This paper discusses new technology that is being developed to allow for real-time monitoring of cell production quality during the biomanufacturing of cell therapies. The aim is to develop a novel switchable biosensor for applications in continuous cell therapy process monitoring. The biosensors incorporate stimuli-responsive technology that allows for the biosensor to be switched on or off electrically for on-demand sensing of cytokines. In this preliminary work, we show the coupling of nanobodies targeted to eGFP via carbodiimide chemistry to immobilize them onto 11-mercaptoundecanoic acid gold screen-printed electrodes (SPE). The gold chips were characterized using spectroscopic ellipsometry and gold SPEs were characterized with cyclic voltammetry and faradaic electrical impedance spectroscopy (EIS). Our results show successful immobilization of GFP nanobodies onto the SPE biosensors and detection of eGFP through EIS and fluorescence microscopy.

In this latest update we highlight: a publication from the US FDA regarding the definitions of real-world data (RWD) and real-world evidence (RWE); a publication from academic researchers on a demonstration project for target trial emulation; a publication from the National Institute of Health and Care Excellence (NICE) on the 1year anniversary of their RWE framework; and a publication from NICE and Flatiron Health on the utility of US RWD for initialUK health technology assessment decision making.

A new electrochemical sensor is reported based on a modified platinum (Pt) electrode sequentially drop-casting doped with functionalized multi-walled carbon nanotubes (fMWCNTs) decorated by reduced graphene oxide (rGO) and nickel oxide (NiO) nanoparticles (NPs). The NiO/rGO/fMWCNTs nanohybrid was characterized by Fourier transform infrared spectroscopy (FT-IR), field emission scanning electron microscopy (SEM), X-ray diffraction (XRD), and X-ray fluorescence (XRF). This sensor was employed for the simultaneous determination of catechol and hydroquinone. In the cyclic voltammetry (CV) results for a binary mixture of catechol and hydroquinone, the peak potentials of the two dihydroxybenzene isomers were separated by more than 105 mV, demonstrating the ability of the fabricated sensor to simultaneously determine the analytes. The NiO/rGO/fMWCNTs/Pt electrode exhibited a wide linear range of 10–300 μM with detection limits of 19.86 and 40.18 nM based upon a signal-to-noise ratio of 3 for catechol and hydroquinone, respectively. Furthermore, using differential pulse voltammetry (DPV), the sensor maintained well-defined peaks, demonstrating suitable selectivity. In addition, the NiO/rGO/fMWCNTs/Pt nanocomposite exhibits stability values of 92.3% and 91.6% for catechol and hydroquinone with excellent repeatability. The sensor analyzed water samples with spike recoveries from 90% to 106.66% for catechol and 88% to 98.66% for hydroquinone, respectively.

Since the COVID-19 outbreak was declared a pandemic by the World Health Organization (WHO) in March 2020, ongoing efforts have been made to develop sensitive diagnostic platforms. Detection of viral RNA provides the highest sensitivity and specificity for detection of early and asymptomatic infections. Thus, this work aimed at developing a label-free genosensor composed of graphene as a working electrode that could be embedded into a flex printed circuit board (FPCB) for the rapid, sensitive, amplification-free and label-free detection of SARS-CoV-2. To facilitate liquid handling and ease of use, the developed biosensor was embedded with a user-friendly reservoir chamber. As a proof-of-concept, detection of a synthetic DNA strand matching the sequence of ORF1ab was performed as a two-step strategy involving the immobilization of a biotinylated complementary sequence on a streptavidin-modified surface, followed by hybridization with the target sequence recorded by the differential pulse voltammetric (DPV) technique in the presence of a ferro/ferricyanide redox couple. The effective design of the sensing platform improved its selectivity and sensitivity and allowed DNA quantification ranging from 100 fg/mL to n}{}1~mu text{g}n/mL. Combining the electrochemical technique with FPCB enabled rapid detection of the target sequence using a small volume of the sample (5-n}{}20~mu text{L}n). We achieved a limit-of-detection of 100 fg/mL, whereas the predicted value was ~33 fg/mL, equivalent to approximately n}{}5times 10^{5}n copies/mL and comparable to sensitivities provided by isothermal nucleic acid amplification tests. We believe that the developed approach proves the ability of an FPCB-implemented DNA sensor to act as a potentially simpler and more affordable diagnostic assay for viral infections in Point-Of-Care (POC) applications.

Hepatic oval cells (HOCs) are considered the progeny of the intrahepatic stem cells that are found in a small population in the liver after hepatocyte proliferation is inhibited. Due to their small number, isolation and capture of these cells constitute a challenging task for immunosensor technology. This work describes the development of a 3D-printed continuous flow system and exploits disposable screen-printed electrodes for the rapid detection of HOCs that over-express the OV6 marker on their membrane. Multiwall carbon nanotube (MWCNT) electrodes have a chitosan film that serves as a scaffold for the immobilization of oval cell marker antibodies (anti-OV6-Ab), which enhance the sensitivity of the biomarker and makes the designed sensor specific for oval cells. The developed sensor can be easily embedded into the 3D-printed flow cell to allow cells to be exposed continuously to the functionalized surface. The continuous flow is intended to increase capture of most of the target cells in the specimen. Contact angle measurements were performed to characterize the nature and quality of the modified sensor surface, and electrochemical measurements (cyclic voltammetry (CV) and square wave voltammetry (SWV)) were performed to confirm the efficiency and selectivity of the fabricated sensor to detect HOCs. The proposed method is valuable for capturing rare cells and could provide an effective tool for cancer diagnosis and detection.

Use of additive manufacturing is growing rapidly in the orthotics field. This technology allows orthotics to be designed directly on digital scans of limbs. However, little information is available about scanners and 3D scans. The aim of this study is to look at the agreement between manual measurements, high-level and low-cost handheld 3D scanners. We took two manual measurements and three 3D scans with each scanner from 14 lower limbs. The lower limbs were divided into 17 sections of 30mm each from 180mm above the mid-patella to 300mm below. Time to record and to process the three 3D scans for scanners methods were compared with Student t-test while Bland-Altman plots were used to study agreement between circumferences of each section from the three methods. The record time was 97s shorter with high-level scanner than with the low-cost (p = .02) while the process time was nine times quicker with the low-cost scanner (p < .01). An overestimation of 2.5mm was found in high-level scanner compared to manual measurement, but with a better repeatability between measurements. The low-cost scanner tended to overestimate the circumferences from 0.1% to 1.5%, overestimation being greater for smaller circumferences. In conclusion, 3D scanners provide more information about the shape of the lower limb, but the reliability depends on the 3D scanner and the size of the scanned segment. Low-cost scanners could be useful for clinicians because of the simple and fast process, but attention should be focused on accuracy, which depends on the scanned body segment.

Vedanā can often be viewed as the somewhat ‘poor relation’ of the practices and reflections that in early Buddhism arose from the Satipaṭṭhāna Sutta, and were central to the Buddha’s teachings arou...

Introduction: Wake Forest Baptist Medical Center has perceived a rise in the number of injection drug use associated endocarditis cases. Many of these patients report injection of the prescription opioid oxymorphone, a drug specifically linked to a microangiopathic hemolytic anemia when injected and large HIV outbreak in Indiana. Hypothesis: 1) The number of IDU-IE cases at our institution is increasing 2) The characteristics of these patients will differ from the classically taught phenotype of a mostly male, right sided predominant, low morbidity and mortality disease process 3) Those who injected oxymorphone will have differing clinical characteristics and clinical outcomes than those who did not inject oxymorphone. Methods: Retrospective analysis of IE cases at an academic medical center from 1/1/2004 to 9/30/2015 stratified by IDU and reported intravenous oxymorphone use. Results: Three hundred seven cases of IE were identified which included 92 IDU cases: 46 oxymorphone-exposed and 46 oxymorphone-unexposed . As compared to the non-IDU group, the IDU group was younger (31.3 +/-9.2 vs 54.2 +/-15.8, p&lt;0.0001), predominantly Caucasian (95.7% vs 78.1%, p=0.0002), and female (58.7% vs 35.4%, p=0.02). When comparing the oxymorphone-exposed to oxymorphone-unexposed group, age (31.3+/-9.2 vs. 33.2+/-9.2, p=.32), race (95.7% Caucasian both groups), and gender (58.7% female vs. 41.3% p=0.1) were equivalent. As compared to the oxymorphone-unexposed group, the oxymorphone exposed group had significantly more MRSA (63% vs 48.9%, p=.007), tricuspid valve involvement (52.2% vs 30.4%, p=.03), and hepatitis C antibody seropositivity (78.3% vs 52.2%, p=.01). The oxymorphone unexposed group had significantly more aortic valve disease (23.9% vs 2.2%, p=.004), cardiac surgery (37% vs 13%, p=.008), and ICU admission (73.9% vs 54.4%, p=.05) than the oxymorphone exposed group. Inpatient mortality was comparable (6.5% exposed vs 8.7% unexposed, p=1.0) whereas one-year mortality was 19.6% in the oxymorphone exposed group and 13% in the oxymorphone unexposed group (p=.06). Conclusions: Our results support the hypothesis that there may be differences in clinical characteristics and outcomes of IDU-IE which are associated with the specific drug of abuse.